At the American Association for Cancer Research (AACR) 2022 Annual Meeting, investigators reported encouraging efficacy and safety data from a phase 1/2 trial (NCT03047928) of a PD-L1/IDO peptide vaccine plus nivolumab (Opdivo) for the treatment of patients with metastatic melanoma....
